ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Growth Hormone
Phase 2

AOD-9604

AOD-9604

Also known as: AOD9604, Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

Overview

Key Facts

Primary Goal: A modified fragment of human growth hormone (amino acids 177-191) with an added tyrosine at the N-terminus

A modified fragment of human growth hormone (amino acids 177-191) with an added tyrosine at the N-terminus. It was developed to isolate the fat-metabolizing activity of GH without its growth-promoting or diabetogenic effects. Half-Life ~30 minutes Typical Dose 250–500 mcg Frequency once daily, fasted Cycle Length 12-24 weeks

Dosing Information

Half-Life

~30 minutes

Typical Dose

250–500 mcg

Frequency

once daily, fasted

Cycle Length

12-24 weeks

Administration Routes:

subcutaneousoral

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Phase 2

AOD-9604 underwent Phase II clinical trials for obesity showing modest but statistically significant fat loss compared to placebo. It received GRAS (Generally Recognized as Safe) status from the FDA in 2014 for use as a food substance. Recent research has pivoted toward its potential in cartilage regeneration and osteoarthritis treatment.

Frequently Asked Questions

Common questions about AOD-9604

UK-Specific Information

Exclusive data points and guidance for UK residents using AOD-9604

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With